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Abstract 
Early menopause and infertility are common consequences of antineoplastic treatments 
in premenopausal women. Since the ability to have biological children is of great importance 
for cancer survivors, the risk of infertility is a source of great distress and lower quality of life 
among these patients. Several procedures can be presented to both men and women at the time 
of diagnosis. Despite increasing awareness, fertility in cancer is not universally discussed, in 
spite of the American Society of Clinical Oncology (ASCO) latest recommendations.  
This review summarized and contextualized the existing research that has been 
conducted on oncofertility, while reflecting on future research and clinical directions, aiming 
to optimize patient care. 
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Despite its higher incidence in 
postmenopausal women, cancer is 
increasingly common in women of 
childbearing age (Assi et al., 2013). Besides 
breast cancer, cervical cancer, thyroid 
cancer, non-Hodgkin’s lymphoma and 
leukemia are the most frequent cancers 
among men and women younger than 40, 
with little difference between different 
countries (Fidler et al., 2017).  
Advances in early diagnosis and 
improved treatment protocols have 
significantly increased these patient 
survival rates, now exceeding 80% for some 
cancer types (Allemani et al., 2018). These 
higher survival rates increase the 
importance placed on survivorship issues, 
such as quality of life and the multitude of 
challenges after successful treatment 
(Anderson et al., 2018). Changes in fertility 
are a potential adverse effect of cancer and 
the neoplastic treatments.  
With the recent voluntary deferral of 
procreation in Western societies, many of 
these men and women, at the time of 
diagnosis, have yet to initiate family or have 
not yet completed their family wishes. 
Although surrogacy and adoption can be an 
option, many cancer survivors voice a 
preference for biological parenting (Oktay 
& Oktem, 2009). Since thousands of cancer 
patients and survivors are in their 
reproductive age, the risk of infertility after 
cancer and its impact on quality of life, 
assumes great clinical significance.  
In this context, Oncofertility 
appeared as an emerging discipline aiming 
to understand cancer patients needs 
regarding their reproductive potential 
before, during and after antineoplastic 
treatments (Woodruff, 2010). As a new 
clinical specialty, it also advocates for the 
timely provision of fertility information and 
for the referral to fertility preservation 
specialists to all cancer patients of 
reproductive age (< 45 years) (Logan, Perz, 
Ussher, & Anazodo, 2017), and for the 
importance of establishing fertility 
preservation as a part of current medical 
practice in oncology (Loren et al., 2013; 




To perform this review, a literature 
search was carried on the descriptors cancer 
and fertility in two different databases: 
PubMed and PsycInfo. No time restrictions 
were applied. Last search was performed in 
December 2018. This review included 





To optimize understanding, this 
review was subdivided into the following 
subheadings: effects of anticancer 
treatments on fertility; fertility preservation 
methods; international recommendations 
regarding infertility risk; health 
professionals’ attitudes towards fertility 
preservation; patient’s concerns and 
attitudes regarding risk of infertility; 
patients' information needs regarding 
fertility preservation; and the impact of the 
risk of infertility in patient’s quality of life.  
 
Effects of anticancer treatments on fertility 
 
The negative effect of cancer 
therapy on fertility is well-known. Some 
chemotherapeutic agents, abdominal or 
pelvic radiation, bone marrow 
transplantation and surgery for 
gynecological malignancies, have a high 
risk of gonadal damage (Alvarez & 
Ramanathan, 2018). Especially 
chemotherapy and endocrine treatments, 
have experienced a significant increase in 
the last decade. These antineoplastic 
treatments may partially or definitively 
affect ovarian function and lead to early 
menopause with all of its inherent risks, 
including infertility, that may be temporary 
or permanent.  
Adjuvant chemotherapy, 
particularly with alkylating agents (such as 




chlorambucil, melphalan, busulfan, and 
procarbazine), poses the greatest risk of 
significant or permanent damages on 
fertility in both men and women (Oktay & 
Oktem, 2009). This agent is responsible for 
high gonadotoxicity and induces 
amenorrhea in 18 to 61% of women under 
40 years. Women who receive this agent are 
four times more likely to develop ovarian 
failure, since it markedly accelerates the 
rate of age-related ovarian follicle loss by 
approximately 10 years (Kim, Klemp, & 
Fabian, 2011).  
When fertility is preserved after 
chemotherapy, specifically in hormone-
dependent breast cancer tumors, women are 
also prescribed with hormonal replacement 
therapy, such as tamoxifen. In these cases, 
women are advised to postpone their 
pregnancy for a minimum of two to five 
years, since the risk of recurrence is higher 
in this time period and this hormonal 
treatment is proposed for a minimum of five 
years. Nevertheless, extending tamoxifen 
up to ten years rather than stopping at 5, has 
been proven to further reduce recurrence 
and mortality, especially after the tenth year 
(Davies et al., 2013). This extension has 
been incorporated into the international 
guidelines for cancer treatment, preventing 
women from considering pregnancy, as 
fertility is also likely to be reduced due to 
age-related decline (Charif et al., 2015). 
Nevertheless, these patients should not be 
discouraged to become pregnant when they 
want to, since research suggested no 
adverse effect of pregnancy on survival (de 
Bree, Makrigiannakis, Askoxylakis, 
Melissas, & Tsiftsis, 2010). Furthermore, 
the research also revealed that local or 
systemic anticancer treatments posed no 
further risks for the offspring of cancer 
survivors. However, since there is a higher 
risk for miscarriage in these situations, there 
are some necessary prerequisites that 
should be considered when supporting a 
pregnancy after cancer. The interval 
between treatment and conception is one of 
the most important considerations, since 
women who conceived less than one year 
after chemotherapy, had higher risks of 
preterm birth than women who conceived 
two years or more after treatment (Hartnett 
et al., 2018).  
 
Fertility preservation methods  
 
Increasing survival rates in 
oncology patients in reproductive age has 
led to the development and increasing use 
of various fertility preservation techniques. 
In male patients, because of advances in 
fertilization and sperm bank technologies, 
sperm cryopreservation is well-established, 
cheap and easily performed (Oktay & 
Oktem, 2009). In female patients, fertility 
preservation procedures are usually more 
expensive, time consuming, requiring of 
more medical expertise, and not as reliable 
as sperm banking in men. Nevertheless, 
given the importance of fertility, especially 
for female patients, there are different 
techniques that can be presented before 
treatment initiation, based on the patient’s 
age and health status, as well as risk of 
ovarian involvement (Rajabi, Aliakbari, & 
Yazdekhasti, 2018) 
Embryo cryopreservation is the 
most well-established option for female 
fertility preservation, as recognized by 
ASCO (American Society of Clinical 
Oncology) and ASRM (American Society 
for Reproductive Medicine) (Loren et al, 
2013; Oktay et al., 2018). This procedure 
involves an ovary stimulation period with 
daily injections of gonadotrophins and 
ultrasonographic monitoring of follicle 
growth, which implies exposure to high 
levels of estrogen and a delay in systemic 
treatment commencement for at least two to 
three weeks. This method also implies that 
there is a source of male gametes, 
sometimes causing the exclusion of women 
who do not have a steady partner (Rajabi et 
al., 2018). In these situations, other viable 
options should be presented, including the 
cryopreservation of oocytes, which also 
require an ovarian stimulation procedure, a 
subsequent follicular puncture and 
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cryopreservation obtained by vitrification. 
This vitrification by freezing technique has 
significantly improved the survival of 
oocytes, fertilization rates and the ratio of 
high-quality embryos due to slow freezing, 
allowing better conservation results (Oktay 
et al., 2018).  
In addition to these two methods, 
there are other experimental options, such 
as ovarian tissue cryopreservation, 
especially useful when hormonal 
stimulation is undesirable and/or there is 
urgency in anticancer treatment initiation. 
This technique, involves a laparoscopic 
surgery for harvesting a fragment of the 
ovary. Hereafter, the ovarian tissue is 
properly prepared and cortex fragments are 
isolated for cryopreservation. Whenever 
necessary, the fragments are thawed and 
grafted on the remaining ovary - orthotopic 
transplantation - or in another location - 
heterotopic transplantation. After 
transplantation, the ovarian tissue can 
restore its endocrine function and fertility 
(Rajabi et al., 2018). Concerning 
gonadotropin-releasing hormone agonist 
(GnRHa), evidence is still inconclusive 
regarding its isolated success for fertility 
preservation during chemotherapy (Oktay 
et al., 2018).  
The American Society of Clinical 
Oncology (ASCO) has recently updated its 
guidelines for fertility preservation in 
cancer patients. If clinically safe and if the 
patient has time before treatment 
commencement, ASCO recommended that 
oocyte cryopreservation should be offered 
(Abdallah et al., 2017; Oktay et al., 2018). 
In addition, ovarian cryopreservation is 
another procedure with great potential in the 
near future (Rajabi et al., 2018).  
Therefore, with the recent advances 
in biomedicine and technology, the 
probability of childbearing after aggressive 
antineoplastic treatments is constantly 
increasing. Nevertheless, fertility outcomes 
in oncology patients have not been 
adequately studied given the small 
percentage of patients that attempted to get 
pregnant after cancer. Many studies have 
reported good results of these procedures, 
but only a few of them reported pregnancy 
outcomes in patients returning to use their 
embryos or oocytes after cancer (Alvarez & 
Ramanathan, 2018; Anderson et al., 2018).  
 
International recommendations regarding 
infertility risk  
 
ASCO recommendations regarding 
fertility preservation encouraged 
oncologists to address the risk of infertility 
with their patients treated during 
childbearing years, to discuss with them 
fertility preservation options and to referee 
them to reproductive specialists (Loren et 
al, 2013; Oktay et al., 2018; Oktay & 
Oktem, 2009). 
First, patients should be informed 
about the feasibility of pursuing fertility 
preservation options and its dependency on 
each patient’s recurrence risk, prognosis 
and risk of infertility or early menopause 
from oncology therapy. Next, fertility 
preservation options should be discussed 
with their respective success rates, 
including those considered experimental. 
Clinicians should also explain that these 
procedures may be time consuming and, 
therefore, subjected to time constraints and 
antineoplastic treatment delay (Loren et al., 
2013; Oktay et al., 2018). Thus, it is 
important to inform patients that there is no 
significant delay in cancer treatment when 
choosing to preserve fertility, and that a 
prompt referral to a fertility specialist 
optimizes the lag time between diagnosis 
and cancer treatment commencement (Lee, 
Ozkavukcu, Heytens, Moy, & Oktay, 
2010). Even though there is a lack of 
evidence, health professionals should also 
explain that there appears to be no increased 
risk of cancer recurrence after fertility 
preservation or/and pregnancy. Meeting 
with a social worker may also be beneficial 
to support decision-making process, to 
consider the financial resources and the 
associated costs of this procedure (Angarita 
et al., 2016; Loren et al., 2013).  
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Although these guidelines represent 
a step forward, additional efforts are needed 
to encourage clinicians to include infertility 
risk as part of the standard discussion for all 
cancer patients within reproductive years. 
This topic is not consistently addressed in 
clinical practice, despite the 
aforementioned ASCO recommendations 
(Angarita et al., 2016), and the provision of 
fertility preservation is still lacking. 
Improvements need to be made in the 
number of referrals from oncology to 
reproductive medicine specialists (Abdallah 
et al., 2017).   
 
Health professionals’ attitudes towards 
fertility preservation  
 
There are many factors that impact 
patients’ access to fertility preservation 
information. A few studies explored health 
professionals’ concerns regarding these 
discussions and, although evidence 
suggested greater awareness, knowledge 
and willingness to discuss this subject with 
patients, many patients receive little 
information on this subject (Abdallah et al., 
2017; Anderson et al., 2015; Angarita et al., 
2016). A qualitative study, reported that 
clinicians voluntarily avoided this subject 
due to their beliefs that fertility would not 
be affected by treatment and that fertility 
preservation treatments are not effective or 
used by patients after cancer (Peddie et al., 
2012). While still acknowledging the 
importance of fertility preservation for the 
patient's quality of life, only 13.5% of 
clinicians revealed to discuss the available 
options. High importance was given by 
almost all physicians (96%) to the quality of 
life after gonadotoxic treatment and to the 
provision of information about fertility 
preservation options (81%). However, 
when asked about the importance of 
infertility after cancer, a smaller percentage 
of physicians (59%) rated it as highly 
important (Louwe et al., 2013).  
Several barriers were identified 
regarding communication in these 
situations, namely the clinician insufficient 
updated knowledge regarding the available 
cryopreservation options, the lack of 
communication and access to reproductive 
medicine specialists, patients’ 
characteristics (prognosis, age, parental 
status, marital status, financial capacity, 
sexual orientation, sexual maturity, HIV 
infection, and whether or not the patients 
initiate the conversation), the clinicians’ 
perception of fertility as a minor issue, the 
fear of disease aggravation due to 
anticancer treatment delay, the availability 
of educational materials, as well as legal 
and ethical issues, such as the subsequent 
use of male gametes (Louwe et al, 2013; 
Peddie et al., 2012; Vindrola-Padros, Dyer, 
Cyrus, & Lubker, 2017).  
These informational and 
communication barriers may prejudice and 
bias patient’s decision-making processes 
and should be addressed with education on 
both health professionals and patients 
(Angarita et al., 2016). Future work should 
ensure that health care professionals receive 
adequate training on how to consent and 
discuss fertility risk and preservation 
options with young patients and their 
partners (Vindrola-Padros et al., 2017). 
Comprehensive counselling should also 
include related issues such as contraception 
use and health implications of early 
menopause (Benedict, Thom, & Kelvin, 
2016).  
Nevertheless, discussion of fertility 
prognosis and risk of recurrence at the time 
of diagnosis, may become an additional 
burden for clinicians. Communication skills 
should also be trained by consultation with 
other health providers, such as clinical 
psychologists and fertility specialists.  
 
Patients’ concerns and attitudes regarding 
risk of infertility 
 
The percentage of female patients 
who are concerned about fertility issues, 
does not appear to be related to prior 
adherence to conservation methods, since 
the proportion of patients to whom this 
possibility was offered is still low (Angarita 
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et al., 2016; Armuand, Wettergren, Nilsson, 
Rodriguez-Wallberg, & Lampic, 2017; 
Banerjee & Tsiapali, 2016; Benedict et al., 
2018; Shnorhavorian et al., 2015). 
Therefore, the percentage of women of 
childbearing age who are worried about 
their fertility after treatment is high and 
ranges between 57 and 66% (Perz, Ussher, 
& Gilbert, 2014). Being worried about the 
reproductive capability is one of the main 
causes of anxiety and psychological distress 
in this population (Howard-Anderson, 
Ganz, Bower, & Stanton, 2012). Risk of 
infertility is reportedly so emotionally 
draining as the cancer diagnosis itself. 
Nevertheless, it is usually considered a 
secondary worry, compared to mortality 
risk (Woodruff, 2010).  
Several studies focused on 
exploring the sociodemographic and 
clinical characteristics related to these 
concerns, revealing that younger patients, 
highly educated, unmarried, professionally 
active, childless, who wish to have children 
and who previously had trouble getting 
pregnant before cancer, are the most 
concerned about the impact of anticancer 
treatments on fertility (Senkus et al, 2014). 
Young and childless women revealed a 
higher desire to become pregnant after 
breast cancer (76%) compared to women 
who already had children (31%) and who 
seemed to be more concerned about the 
possibility of recurrence (Senkus et al., 
2014).  
Regarding clinical variables, studies 
were mainly focused on time since 
diagnosis, cancer stage, disease 
dissemination and the quality of the 
information received, as factors correlated 
with infertility concerns and willingness to 
undergo fertility preservation procedures. 
Thus, when dealing with cancer diagnosis 
and, especially in a situation of an early-
stage cancer, women revealed to be less 
concerned about fertility preservation, 
while being more focused on anticancer 
treatment and survival (Senkus et al., 2014).  
Considering disease stage, studies 
hypothesized that higher cancer stages (and, 
therefore, with higher risk of recurrence) 
are associated with greater acceptance of 
cancer treatments and its side effects 
(Senkus et al., 2014). Even so, fertility is 
important regardless of cancer stage and, 
therefore, the opportunity for preservation 
should be openly discussed with these 
patients as well (Loren et al., 2013; Oktay et 
al., 2018). 
Regarding patients’ attitudes 
towards fertility preservation, the European 
Organization for Research and Treatment of 
Cancer developed a study aiming to 
evaluate the proportion of participants who 
would not agree to chemotherapy if it 
affected their fertility. The authors found 
that, although survival and cure were the 
priority for young women with cancer, 
fertility preservation emerged as a matter of 
great importance. Results revealed that 59% 
of women from this study wished to have 
children (or more children), compared to 
36% of women who do not want to have any 
more children for fear of recurrence. 
Women who had an easier acceptance of 
risk of infertility were women who already 
had children, did not intend to have more 
children, who were still waiting for the 
beginning of treatment t (initial stage of the 
disease), and living in Western Europe 
(Senkus et al., 2014).  
Studies also revealed that only 29% 
of the patients admitted that their concern 
about future fertility had an impact on 
treatment decision-making, 30% would 
postpone cancer treatment up to one month 
for fertility preservation (Tschudin et al., 
2010), and only a small percentage of 
patients (<10%) would question the need 
for adjuvant treatment if their reproductive 
capability was at risk (Senkus et al., 2014).   
In general, female patients revealed 
more positive than negative attitudes 
towards fertility preservation, which leads 
to the hypothesis that they are receptive to 
decide in favor of fertility preservation 
procedures, when correctly informed 
(Tschudin et al., 2010). Among males, those 
without a college degree, lacking private 
insurance and with children with less than 
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18 years, were more likely to not make 
fertility preservation arrangements 
(Shnorhavorian et al., 2015).  
 
Patient information needs regarding 
fertility preservation 
  
Research is also consistent in 
revealing that patients are generally 
uninformed about fertility preservation 
procedures, presenting low levels of literacy 
regarding this medical issue (Angarita et al., 
2016; Banerjee & Tsiapali, 2016; Peddie et 
al., 2012). Regarding information, 43 to 
62% of female cancer survivors reported 
important unmet information needs 
(Benedict et al., 2018), 26% felt that 
infertility risk was not well addressed by 
their doctors and revealed to be dissatisfied 
with the received information (Charif et al., 
2015). 
There seems to be a number of 
reasons why young women refrained from 
having these discussions with their 
clinicians, such as feeling overwhelmed 
with their cancer diagnosis or being 
unaware of the possible treatment impact on 
fertility (Loren et al., 2013). In 
consequence, 38% of women reported not 
making arrangements for fertility 
preservation because they were unaware of 
the options available, whereas 19% reported 
having financial and cost issues 
(Shnorhavorian et al., 2015).  
Several studies focused on 
identifying the main barriers regarding the 
search for fertility conservation procedures. 
The results showed that one important 
barrier is the way information is delivered 
by oncologists and the emphasis they put on 
the urgency of starting anticancer 
treatments (Peddie et al., 2012). A 
reasonable percentage of patients (33.8%) 
revealed never discussing this subject with 
their husband, family, friends and/or health 
professionals because they felt that 
infertility risk was devalued and considered 
a minor issue when facing cancer (Tschudin 
et al., 2010). Additionally, patients older 
than 35 years and with children were less 
likely to be informed about preservation 
options, and only 52% with chart-
documented discussions regarding this 
subject, recalled having these conversations 
with their clinicians (Banerjee & Tsiapali, 
2016). Consistently, studies pointed 
towards the need to inform patients about 
the anticancer treatments impact on fertility 
and on the existing preservation methods, 
regardless of their sociodemographic or 
clinical characteristics (Armuand, 
Wettergren, Rodriguez-Wallberg, & 
Lampix, 2015; Peddie et al., 2012; 
Tschudin et al., 2010).  
Furthermore, some patients felt that 
there was a bias between the information 
that was delivered and the relevance the 
clinicians gave to the matter, while other 
patients revealed feeling pressured to start 
anticancer treatment and, therefore, not 
having enough time to think about the 
subject and make an informed decision 
(Dagan, Modiano-Gattegno, & Birenbaum-
Carmeli, 2017). This could be the reflection 
of a judgment-bias regarding the clinicians’ 
perceptions when considering the 
importance patients gave to their fertility 
after surviving cancer, which emphasizes 
the importance of how the information was 
delivered that may also impact the patient’s 
decision-making processes (Louwe et al., 
2013).  
Patients comments on qualitative 
research, also highlighted the difficulty of 
considering fertility at the time of diagnosis. 
Hence, the need for more information 
seems to be less prominent at diagnosis, but 
increases during and after systemic 
anticancer treatments. After treatment, 
patients recognize the importance of 
discussing fertility prior to the beginning of 
the treatment (Peate, Meiser, Hickey, & 
Friedland, 2009) and revealed some 
disappointment regarding the quality and 
quantity of the information provided 
regarding their infertility risk and 
preservation options (Armuand et al., 
2015).  
Although fertility was not the 
priority at diagnosis, some women revealed 
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regret for not choosing to take preservation 
into consideration when it was possible. 
Research on decisional regret confirmed 
that women’s perspectives on fertility 
changes over time, from the perception that 
procreation was not important to feeling 
regret over not having pursued conservation 
(Armuand et al., 2017). These studies also 
revealed that pre-treatment fertility 
satisfactory counselling, leads to lower 
levels of post-treatment regret and better 
quality of life (Benedict et al., 2018). Lack 
of information regarding fertility risks can 
have important psychosocial consequences 
(Armuand et al., 2015), and lead to patient’s 
uncertainty, depression, anxiety, distress, 
anger and confusion (Assi et al., 2018; 
Charif et al., 2015).  
More research is needed to 
understand what are the decision-making 
factors underlying fertility preservation. 
Research available is mostly cross-sectional 
and retrospective and there is a lack of 
longitudinal studies that may contribute to a 
better knowledge about patients’ concerns, 
needs and attitudes regarding infertility 
risks, as well as how it evolves over time. 
Research should also focus on exploring 
individual risk factors for decision-regret in 
women with cancer in childbearing age and 
what are their future expectations regarding 
their reproductible capability and family 
plans. Only then, clinicians will have clear 
guidelines on how to educate patients about 
fertility preservation alerting for the 
possibility of mind changing processes, 
while encouraging the discussion of 
situations that might not seem urgent at the 
moment of diagnosis but will affect the 
long-term quality of life. 
 
Impact of the risk of infertility in patient’s 
quality of life  
  
In non-clinical populations, 
infertility has been correlated with high 
levels of anxiety, depression, sadness, sense 
of loss, insomnia, lower self-esteem, 
threatened femininity, lower sexual and 
marital satisfaction, sense of life 
interrupted, social avoidance, greater 
stigma, unsatisfying social relationships, 
and reduced quality of life, when compared 
to couples with no fertility problems (Pedro, 
2018).  
In oncology settings, recent studies 
indicated that the potential for fertility loss, 
may be more stressful than a cancer 
diagnosis itself (Assi et al., 2018). Infertility 
seems to be associated with high levels of 
distress, anxiety and depression (Howard-
Anderson et al., 2012), and lower quality of 
life (Assi et al., 2018). It has also been 
identified as an experience marked by 
feelings of grief and loss, even in women 
who have fulfilled their family wishes 
before cancer (Peate et al., 2009). 
Especially young and childless women with 
breast cancer, revealed higher levels of 
psychological distress, lower self-esteem, 
uncertainty, relationship problems, more 
intrusive thoughts and more avoidance 
strategies (Armuand et al., 2017; Assi et al., 
2018), regardless of cancer site.  
Nevertheless, it is important to 
mention that some studies also revealed that 
even women who already had children and 
who did not think about having more 
children after cancer, also face the risk of 
fertility loss as an emotionally draining 
experience (Peate et al., 2009). Even tough 
70% of patients revealed that the disease 
had no impact on their desire to have 
children, 13 to 15% stated that cancer 
diagnosis increased their desire to be 
mothers again and the value given to 
parenting (Armuand et al., 2015).  
Hence, infertility seems to increase 
the psychological distress associated with a 
cancer diagnosis, regardless of the patients’ 
parental status, since it interferes with 
women’s ability to decide about her life 
project regarding reproducibility and was 
imposed by the disease process, instead of 
her own decision-making. Therefore, even 
patients who did not intend to have children 
before the diagnosis, can feel the loss and 
the anger associated with infertility risk as a 
result of cancer and its treatment. 
Considering this, and since fertility is 
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usually described as an important part of the 
definition of being a woman, all patients 
should be informed about their infertility 
risk due to anticancer treatment, regardless 
of whether or not they have decided to have 
more children in the future.   
In summary, few studies have 
evaluated the impact of fertility on female 
survivors’ quality of life, including 
childhood cancer survivors. Little is known 
about the psychological impact of infertility 
risk during and after cancer treatment, or 
which individual variables can potentially 
protect or impact the quality of life in these 
situations. Based on studies conducted with 
infertile couples from non-clinical 
populations, one can understand that 
infertility has a great impact in several 
individual, relational and social domains 
and it becomes a threatening issue for 
quality of life, well-being, and satisfaction 
with life. Infertility in young women with 
breast cancer is another setback to their 
personal and relational development 
considered another great loss caused by 
cancer. Therefore, it is important to better 
understand the impact of infertility in 
patients’ overall functioning, so that 
strategies can be developed to facilitate 
doctor/patient’s communication processes 




Several studies confirmed the 
cruciality of biological parenting for cancer 
patients of reproductive age (Armuand et 
al., 2015; Assi et al., 2018; Benedict et al., 
2018).  
This review emphasized that the risk 
of infertility exceeds the diagnostic and 
clinical dimension of cancer, and is of great 
significance especially in female patients, 
since it endangers a fundamental life goal 
for most women: the opportunity of 
biological motherhood with several 
psychological, social, and spiritual 
implications for the couple and the family.  
It is important that health 
professionals do not make assumptions 
regarding fertility, since studies 
consistently indicate that patients, 
regardless of their clinical and 
sociodemographic characteristics, assess 
positively the possibility of discussing this 
issue with their oncologist. As a result, 
patients become more satisfied with the 
health care they received, regardless of 
choosing or not to preserve fertility (Peate 
et al., 2009).  
Additionally, oncologist should 
consider that discussing infertility risk with 
patients does not implicate treatment 
adherence (Senkus et al., 2014) and, 
therefore, all the risks, options and benefits, 
should be clearly and carefully addressed, 
ensuring that the patient makes an informed 
decision (Peddie et al., 2012). Health care 
providers should discuss the possibility of 
infertility with adult patients and with 
parents of children diagnosed with cancer, 
as early as possible and address fertility 
preservation options and refer all potential 
interested patients to appropriate 
reproductive specialists. Although patients 
may be more focused on their diagnosis, 
oncologists should advise patients 
regarding potential fertility threats, present 
them with different options and prevent 
future regrets (Oktay et al., 2018).  
Health professionals, while focusing 
on providing their patients quality care, 
should also encourage treatment adherence 
and fighting spirit, but also create 
opportunities for the patients to present its 
questions and concerns on all the subjects 
regarding their disease. Some attitudes of 
positive thinking and encouragement to 
proceed with treatments while facing their 
extensive side-effects, can be evaluated as 
forms of diminishing patients’ concerns, 
inhibiting them to expose their true feelings 
and fears (Peddie et al., 2012).  
Future studies should also identify 
an optimal approach to include fertility 
counselling and support resources into 
patients and survivor care programs. 
Infertility risk should also be included in 
informed consent about anticancer 
treatment (Loren et al., 2013; Vindrola-
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Padros et al., 2017), especially before 
chemotherapy and endocrine therapy. 
Therefore, there is a need to develop 
informational materials (Bradford, Walker, 
Henney, Inglis, & Chan, 2018), clinical 
guidance and multidisciplinary 
consultations. 
Research has already validated the 
existence of barriers in communication 
between patients and health professionals, 
regarding information on infertility risk and 
preservation procedures. Nevertheless, 
more information is needed on which 
individual and contextual factors might 
influence the patient's decision-making 
process.  
To date, research focused on the 
psychological impact of infertility risk in 
cancer patients is still scarce. Studies are 
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